Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients
Metadatos
Afficher la notice complèteAuteur
Gutiérrez Bautista, Juan Francisco; Rodríguez Nicolás, Antonio; Rosales Castillo, Antonio; López Ruz, Miguel Ángel; Martín Casares, Antonia María; Fernández Rubiales, Alonso; Anderson, Per Olof; Garrido Torres-Puchol, Federico; Ruiz-Cabello Osuna, Francisco; López Nevot, Miguel ÁngelEditorial
Elsevier
Materia
HLA polymorphisms COVID-19 SARS-CoV-2
Date
2021-08-25Referencia bibliográfica
Juan Francisco Gutiérrez-Bautista... [et al.]. Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients, Journal of Microbiology, Immunology and Infection, Volume 55, Issue 3, 2022, Pages 421-427, ISSN 1684-1182, [https://doi.org/10.1016/j.jmii.2021.08.009]
Patrocinador
Instituto de Salud Carlos III - FEDER funds (European Union) PI 16/00752; Junta de Andalucia CTS-143 C-0013-2018; RAFER S.L.Résumé
Background: Human leukocyte antigen (HLA) plays an important role in immune responses
to infections, especially in the development of acquired immunity. Given the high degree
of polymorphisms that HLA molecules present, some will be more or less effective in
controlling SARS-CoV-2 infection. We wanted to analyze whether certain polymorphisms may
be involved in the protection or susceptibility to COVID-19.
Methods: We studied the polymorphisms in HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and
HLA-DQB1) molecules in 450 patients who required hospitalization for COVID-19, creating one
of the largest HLA-typed patient cohort to date.
Results: Our results show that there is no relationship between HLA polymorphisms or haplotypes
and susceptibility or protection to COVID-19. Conclusion: Our results may contribute to resolve the contradictory data on the role of HLA
polymorphisms in COVID-19 infection.